Reig Jofre closed the first half of 2026 with revenue of €168.5 million, up 1% year-on-year, and EBITDA of €17.9 million, 27% higher than in the same period of 2025. The EBITDA margin reached 10.7% (8.5% in H1 2026), driven by strong performance in the osteoarticular and dermatology areas and the gradual recovery of the antibiotics business.
Consolidated profit stood at €3.4 million, compared with €1.5 million in the first half of the previous year, an increase of 126%. This improvement came despite higher financial expenses and the impairment of certain assets, the recovery of which is linked to outstanding payments from the insurer.
On the industrial side, one of the quarter’s main milestones was the approval and start-up of the new penicillin-based injectable antibiotics line at the Toledo plant. The facility, equipped with more automated and efficient technology, will gradually increase annual production capacity by around 50% and improve the company’s competitiveness. The new capacity was already reflected in sales, with the antibiotics business growing 16% during the second quarter. Reig Jofre expects, however, that the most significant impact of the new line will be felt gradually from the second half of the year onwards.
At the same time, the company has normalised Forté Pharma’s supply chain in France and Belgium after overcoming the temporary disruption caused by the fire in March, and continues to consolidate the commercial performance of dalbavancin, its non-penicillin injectable antibiotic.
With these developments, Reig Jofre is seeking to strengthen its antibiotics business and move towards a more profitable and sustainable growth model. Optimising its product portfolio, modernising its facilities and improving production efficiency are shaping up as central pillars of its strategy for the coming years.
Source: https://reigjofre.com/wp-content/uploads/2026-07-31-NOTA-RESULTADOS-2T-ES.pdf
